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Long-term survival rates of cancer patients represent important information for policymakers and providers, but
analyses from voluntary cancer registries in Japan may not reflect the overall situation. In 2003, the Diagnosis
Procedure Combination Per-Diem Payment System (DPC/PDPS) for hospital reimbursement was introduced in
Japan; more than half of Japan’s acute care beds are currently covered under this system. Administrative data
produced under the DPC system include claims data and clinical summaries for each admission. Due to the large
amount of data spanning multiple institutions, this database may have applications in providing a more general
and inclusive overview of healthcare. Here, we investigate the use of administrative data for analyses of long-term
survival in cancer patients. We analyzed postoperative survival in 7,064 patients with primary non-small cell lung
cancer admitted to 102 hospitals between April 2008 and March 2013 using DPC data. Survival was defined at the
last date of examination or discharge within the study period, and the event was mortality during the same period.
Overall survival rates for different cancer stages were calculated using the Kaplan-Meier method. Additionally,
survival rates of cancer patients at clinical stage IA were compared between low- and high-volume hospitals
using the Log-rank test. Postoperative 5-year survival for patients at stage IA was 85.8% (95% CI = 78.6%–93.0%).
High-volume hospitals had higher survival rates than hospitals with lower volume. Our findings using large-scale
administrative data were similar to previous clinical registry reports, showing potential applications as a new
method in analyzing up-to-date healthcare information.
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Survival rates of cancer patients are a major concern for
both patients and physicians, and are often referred to
when determining patient prognoses and care strategies.
Cancer registries at the national level support the study
of cancer etiology and outcomes, including analyses of sur-
vival rates (McLaughlin et al. 2010). In the US, the National
Program of Cancer Registries was established in 1992
and provides population-based surveillance. In Europe, the
European Network of Cancer Registries (http://www.encr.
eu/) and the European Cancer Registry (http://www.euro-
care.it/) have been promoting collaborations between can-
cer registries within Europe and the European Union for* Correspondence: imanaka-y@umin.net
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in any medium, provided the original work is pmore than 20 years. While national cancer registrations are
also conducted in Scandinavia and the UK, (Butler et al.
2013) population-based registries in other countries fre-
quently cover only a small portion of the population (Butler
et al. 2013). Among these, German registries have pro-
gressed to a coverage of 40% in 2012 (Hiripi et al. 2012).
Cancer registrations in Japan are still in the process of
development. There exists a population-based cancer regis-
try (http://www.jacr.info/); a hospital-based cancer registry
(http://ncc.ctr-info.com/); and “organ-based” registries ad-
ministrated by various medical associations and organiza-
tions, such as the Japanese Joint Committee for Lung
Cancer Registration (http://haigan-touroku.jp/). However,
these registries possess several shortcomings: for example,
the population-based cancer registry has been reported to
contain omissions of cases, and survival analyses have not
been conducted (Sobue et al. 2007). The hospital-basedis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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hospitals, (Sobue et al. 2007). and registries managed by
medical associations generally include only voluntary par-
ticipations. All of these registry databases do not adhere to
a single format, and there is no framework that allows for
their simple integration (Sobue et al. 2007; Hirata et al.
2012). Furthermore, medical associations conduct and re-
port highly detailed surveys, but tend to struggle with low
respondent rates (Sawabata et al. 2011).
The ability to conduct survival analyses using large-
scale administrative data, such as healthcare claims data-
bases, would provide valuable information on patient
prognoses and treatment effectiveness for a population.
In 2003, Japan introduced a hospital reimbursement sys-
tem known as the Diagnosis Procedure Combination/
Per-Diem Payment System (DPC/PDPS). This system is
characterized by a requirement for healthcare providers
to generate DPC data for each patient per hospitalization
for reimbursement purposes. DPC data are uniformly
formatted and include not only claims data and proce-
dures, but also summaries of patient clinical information
such as principal diagnoses and activities of daily living
(ADL); in the case of cancer patients, the data also in-
clude disease-specific information, such as whether the
cancer is primary or recurrent and the TNM classifica-
tion of malignant tumors. In this way, the DPC/PDPS is
in effect a registry of sorts for cancer patients who re-
ceive treatment at these hospitals.
Relatively short-term indicators for acute diseases,
such as 30-day mortality and in-hospital mortality, have
been widely studied (Lee et al. 2013; Sasaki et al. 2013;
Yamashita et al. 2013) and applied as quality indicators
(The Joint Commission 2014). Long-term survival may
also be considered as a possible measure to describe the
quality of healthcare. Although it should be kept in
mind that long-term survival can be influenced by
various determinants including environmental factors,
differences in patient survival rates among institutions
and regions are a common concern and have been studied
(Meyerhardt et al. 2003; Hebert-Croteau et al. 2005).
Research using administrative data may allow the investi-
gation of hospitals that do not participate in any cancer
registry as well as hospitals across the boundaries of exist-
ing registries. The majority of acute care hospitals in Japan
are reimbursed under the DPC system: over 1,400 hospitals
are managed under this system as of 2013, and constitute
more than 50% of all hospital beds in Japan. The clinical
information available in these databases has allowed re-
searchers in Japan to analyze medical care at the national,
regional, hospital, and individual levels. With the increasing
use of such administrative data for analyses, we are now
able to shed light on relatively small hospitals that have po-
tentially played a considerably large role in Japanese health-
care, but have heretofore been unavailable for analysis.In 1995, our department established the Quality Indi-
cator/Improvement Project (QIP; http://med-econ.umin.
ac.jp/QIP/) in order to improve quality of healthcare in
participant hospitals through the development, analysis,
and feedback of quality indicators. Hospitals voluntarily
participate in this project, and there are more than 400
hospitals currently enrolled. These participant hospitals
continuously provide DPC data to the QIP; this data is
analyzed and the results are periodically reported in
feedback to participant hospitals. As this project has in-
volved the collection of data for a relatively long period,
it has developed the capacity for long-term analyses.
In this study, we attempt to open a new vista to con-
duct survival analyses of cancer patients using adminis-
trative data, focusing our analysis on postoperative lung
cancer patients. This sample was selected due to the high
incidence of the disease and high mortality rate of the pa-
tients, (Ministry of Health, Labour and Welfare 2013)
thereby making this one of the most important fields in
health services research. Our analysis may reveal up-to-
date details of patient survival with relatively high external
validity, as our sample includes hospitals not currently en-
rolled in any cancer registry. Additionally, we investigate if
there are differences in long-term survival among hospi-
tals according to patient volume; the volume-outcomes re-
lationship has been demonstrated in previous studies, and
we analyze if our database and methodology are able to
obtain similar conclusions to these registry-based studies.
Methods
Data
In this retrospective cohort study, we analyzed the postop-
erative survival of non-small cell lung cancer patients
using administrative data. The data were obtained from
the DPC-formatted database administered by the QIP.
This database is very different from those of clinical regis-
tries: registries usually collect specific data for predeter-
mined purposes and these data are submitted intentionally
for analysis. In contrast, the DPC database uses medical
claims data, which are routinely produced for all medical
services with the primary intended purpose of reimburse-
ment. These claims data are collected and analyzed to de-
tect the statuses and progress of patients (Figure 1).
Non-small cell lung cancer patients were identified
using International Classification of Diseases, 10th revi-
sion (ICD-10) codes C34$ combined with cancer-specific
information from the DPC data. Patients were included in
analysis if they had been discharged from QIP member
hospitals between April 2008 and March 2013 with the
complete data necessary for our study. Although DPC
data are produced either for inpatients or for both inpa-
tients and outpatients depending on hospital, we selected
hospitals that had contributed both inpatient and out-
patient data to the database.
Figure 1 Data collection and analyses. All medical claims data produced for each hospitalization and subsequent outpatient visits are collected
into a database, which is then analyzed in order to detect and trace statuses and progress of individual research subjects.
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were identified from inpatient data. We selected patients
who had undergone an operation for the first time for pri-
mary non-small cell lung cancer. We investigated patient-
level treatment histories from both the inpatient and out-
patient database, and identified the last date of medical
care or examination for each patient. Survival time was
defined as the duration from the date of the initial oper-
ation for non-small cell lung cancer to the last recorded
date for any medical service provided in the same hospital.
For the survival analysis, the event was defined as patients
who had died on the last recorded date for medical ser-
vices, and surviving patients at the last recorded date were
regarded as right censored.
It should be noted that the treatment histories for a sin-
gle patient could only be followed for treatments provided
in the same hospital. Therefore, censored cases include
cases lost to follow-up due to changes in hospital, in
addition to censoring resulting from the end of the study
period. For this study, we assumed that the majority of pa-
tients would obtain healthcare from the same hospital
after operation, as follow-up care would likely be con-
ducted by specialists who are familiar with the patients.
Data concerning the base characteristics of patients and
clinical TNM classification of cancer were also analyzed.
We reclassified the TNM classes according to overall stage
grouping. Because the study period included a transitional
period with regard to the shift from Union for Inter-
national Cancer Control (UICC)-6 to UICC-7 classifica-
tion, our analysis included an overlap of both types of
classification. We identified and standardized equivalent
stages from the different staging standards for analysis: for
example, T2N0M0 was equivalent to Stage IB in UICC-6;
but under the current UICC-7 classification, Stage IB isequivalent to T2aN0M0 and Stage IIA is equivalent to
T2bN0M0. Thus, a classification of Stage IB in this study
includes both T2N0M0 of UICC-6 classification and
T2aN0M0 of UICC-7 classification. We selected patients
at Stages IA–IIIA for analysis.
Comparison of survival rates according to patient volume
In addition, we compared survival rates between high-
volume and low-volume hospitals. The relationship be-
tween patient volume and quality of healthcare has been
widely reported, but there remains a lack of consensus on
the nature of the relationship (Merlino 2007; Luchtenborg
et al. 2013; Howington et al. 2013). We divided hospitals
into two groups: those that had performed 30 or more op-
erations per year, and those with fewer than 29 operations
per year. For ease of comparison, we limited this analysis
to patients with non-small cell lung cancer of stage IA
(T1N0M0 in both UICC-6 and UICC-7) and who were
completely independent with regard to ADL (i.e., patients
with a score of 100 points in the Barthel Index).
Statistical analysis
Overall survival time for the various cancer stages was
calculated using the Kaplan-Meier estimator with 95%
confidence intervals (CIs).
To analyze the effect of patient volume on the survival
of postoperative stage IA lung cancer patients, we utilized
the Log-rank test. All statistical analyses were conducted
using SPSS software, Version 20.0.0.2 (IBM Inc., Japan).
Ethical standard
Prior to the study, the study procedures were reviewed
and approved (#E553) by the ethics review committee of
Kyoto University Graduate School of Medicine, and
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the Ethical Guidelines for Epidemiological Research of
the Japanese national government, which include guidelines
on protecting patient anonymity, and all the necessary con-
ditions were satisfied for informed consent to be waived.
Results and discussion
Results
Survival rates of postoperative non-small cell lung cancer
patients
We analyzed 7,064 primary non-small cell lung cancer
patients from 102 hospitals. The various survival ratesTable 1 Clinical stage–specific survival rates (1 year to 5 year
Su
N 1Y
Clinical stages (DPC data) % 95% CI na %
IA 3812 98.2 (±0.6) 2014 96.3
IB 1581 95.4 (±1.2) 781 90.7
IIA 420 94.6 (±2.5) 200 87.8
IIB 480 86.4 (±3.7) 230 71.7
IIIA 771 89.1 (±2.5) 386 78.7
JJCLCR (2011) Clinical stages 6th editionb
IA 6295 97.0 92.7
IB 2788 91.0 81.9
IIA 203 89.7 75.0
IIB 899 83.7 69.5
IIIA 940 80.9 64.3
JJCLCR (2011) Clinical stages 7th editionb
IA 6295 97.0 92.7
IB 2339 92.5 84.4
IIA 819 88.7 85.4
IIB 648 80.0 63.6
IIIA 1216 81.4 64.7













bData from the Japanese Joint Committee for Lung Cancer Registration (JJCLCR) in
cData from the International Association for the Study of Lung Cancer (IASLC) in 20(1 year to 5 years) in stage IA to IIIA patients are pre-
sented in Table 1. The postoperative 5-year survival rate
for stage IA patients was 85.8% (95% CI = 78.6% - 93.0%).
There were substantially more cases with Stages IA and
IB when compared with the other stages. For compara-
tive purposes, Table 1 also shows survival rates from pre-
vious reports by the Japanese Joint Committee for Lung
Cancer Registration (JJCLCR) in 2011 (Sawabata et al.
2011) and the International Association for the Study
of Lung Cancer (IASLC) in 2009 (Tanoue and Detterbeck
2009). Figure 2 shows the Kaplan-Meier curves for
overall survival.s) of postoperative non-small cell lung cancer patients
rvival rates (%) and number of subjects at risk
2Y 3Y 4Y 5Y
95% CI n % 95% CI n % 95% CI n % 95% CI
(±0.8) 939 92.6 (±1.8) 318 89.3 (±3.1) 36 85.8 (±7.3)
(±2.2) 365 86.6 (±2.9) 137 85.0 (±3.7) 25 85.0 (±3.7)
(±4.7) 84 78.0 (±8.0) 21 73.9 (±11.0) 4 24.6 (±39.6)
(±5.9) 92 66.3 (±7.6) 34 58.6 (±10.6) 7 58.6 (±10.6)





















2011 (Sawabata et al. 2011); 95% CI were not available for these data.
09 (Tanoue and Detterbeck 2009); 95% CI were not available for these data.
Figure 2 Survival curves according to clinical cancer stage. Survival curves according to clinical cancer stage for surgically managed primary
non-small cell lung cancer patients.
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For the analysis of survival according to patient volume,
the sample consisted of 3,379 patients at clinical stage IA
with complete independence in terms of ADL. The high-
volume hospital group comprised 33 hospitals with 2,587
cases, and the low-volume hospital group comprised 63
hospitals with 792 cases. The base characteristics of these
patients are shown in Table 2, and Chi-square tests re-
vealed no significant differences (P > 0.05) in gender and
ages between the two hospital groups. The effect of pa-
tient volume on survival was assessed using the Log-rank
test for the Kaplan-Meier survival curves. Table 3 and
Figure 3 show the survival rates of each group. The 5-year
survival rates for high-volume hospitals and low-volume
hospitals were 92.1 ± 2.9% and 81.4 ± 11.1%, respectively;
the results showed a significant difference between the
groups (p = 0.05).
Discussion
In this study, we conducted postoperative survival ana-
lyses of lung cancer patients using an administrativeTable 2 Base characteristics of patients admitted to
low-volume hospitals (n = 63) and high-volume hospitals
(n = 33)
Low-volume hospitals High-volume hospitals
Gender Male 467 1463
Female 325 1124
Age <65 y 246 857
65–74 y 288 986
≥75 y 258 744
Death 29 52
Total 792 2587
Values in the table indicate numbers of patients.database. As shown in Figure 2, survival rates varied
substantially among the clinical stages. The findings
were similar to those in previous Japanese reports that
utilized registry data, (Sawabata et al. 2011) which sup-
ports the applicability of our administrative data–based
method. The second analyses showed that our findings
corroborate the results from previous studies in which
higher volume hospitals showed a higher survival rate.
The contribution of this study to the field lies in the
use of large-scale administrative data to analyze long-
term postoperative survival. The comparably larger sam-
ple sizes for Stages IA and IB strengthen the validity of
our findings; however, the sample sizes were smaller in
later-stage cancer, and the details of survival rates for
these groups were more difficult to discern. The survival
rates for the two early stages were very similar to those
previously reported in Japan, (Sawabata et al. 2011)
which supports the applicability of this method, al-
though it should be noted that the figures were very
different from those in an international report (Tanoue
and Detterbeck 2009). Survival rates in this study were
slightly higher than those previously reported in Japan
(Tanoue and Detterbeck 2009). This discrepancy may be
the result of a possible bias in our study due to the loss
to follow-up of patients who had died in a different hos-
pital from the initial hospital where the operation was
conducted, which is discussed in further detail below.
Alternatively, the differences in results may be due to
the differences in composition of the study samples,
wherein our analysis may have contained more general
hospitals than analyses using only hospitals enrolled in
cancer registries. Also, the differences in study periods
between our analysis and previous studies may have
contributed to the observed differences in survival rates.
Our study comprises up-to-date data, and may have
Table 3 Survival in surgically managed primary non-small cell lung cancer patients with a clinical stage of IA categorized
by patient volume per hospital
Survival rates (%) and number of subjects at risk
N 1Y 2Y 3Y 4Y 5Y
Patient Volume % 95% CI na % 95% CI na % 95% CI na % 95% CI na % 95% CI
High-volume Hospitals 2587 98.5 (±0.6) 1336 97.3 (±0.5) 614 93.9 (±1.1) 195 92.1 (±2.9) 3 92.1 (±2.9)
Low-volume Hospitals 792 97.8 (±1.2) 427 94.9 (±2.4) 163 90.6 (±4.5) 50 81.4 (±11.1) 18 81.4 (±11.1)
aNumber at risk.
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studies are needed to clarify these differences.
The data used in our analysis were only obtained from
the administrative data submitted by each hospital, and
were not merged with external data sources such as popu-
lation databases or registration databases. Database integra-
tion in Japan presents considerable difficulties due to a lack
of national unique identification data, such as social se-
curity numbers or national insurance numbers. DPC data
may represent a tool to overcome these difficulties, as hos-
pitals under the DPC/PDPS encompass more than half
of all acute care beds in Japan, and treat approximately
90% of all acute inpatients (Murata et al. 2013). As DPC
data are uniformly formatted, quick multi-institutional
analyses are possible and can provide valuable up-to-date
information for policymakers, healthcare providers, and
the general public.
Hospitals with different patient volumes were found to
have different survival rates in our study, which was com-
patible with previous reports wherein higher volume hospi-
tals showed more favorable outcomes (Merlino 2007;
Luchtenborg et al. 2013; Howington et al. 2013). Further-
more, as DPC data contain some clinical information, risk
adjustment is possible. Owing to prompt analysis, the use
of these data may allow long-term survival to be estab-
lished as a quality indicator, with applications in comparingFigure 3 Survival and patient volume per hospital. Survival curves by p
cell lung cancer patients with a clinical stage of IA.regional variations or identifying hospitals with exception-
ally low survival rates.
Another point worth noting is that this method can be
adapted to other patient populations, such as for other
cancers and other diseases. Furthermore, this type of
study may have applications in countries other than
Japan. Japanese DPC data may serve as a model when
designing or reforming other insurance claims databases,
as this system not only enables analyses of in-hospital
situations, but also provides useful medical data for ana-
lyzing patients after being discharged.
Another novelty of this study is that owing to the ex-
tensive database, we were able to deal with relatively
large sample sizes for each analysis. The benefits of
large-scale analysis were demonstrated in the narrow
95% CIs; even the CIs around 5-year survival—which
was the full time period of our study—were considerably
narrow, indicating a level of reliability in our findings. In
other words, we were able to fully utilize the inpatient
data spanning a 5-year period by evaluating 5-year sur-
vival rates. This was largely due to the use of the
Kaplan-Meier method. When the sample size is rela-
tively small, researchers need to wait for many years to
obtain a sufficient sample size for an analysis: for ex-
ample, several years may be required to enroll sufficient
cases and several more years to conduct observationsatient volume per hospital for surgically managed primary non-small
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lection period. However, the DPC data allow quick and
up-to-date insight into patient survival over several
years, which can support medical staff and policymakers
in monitoring current cancer treatments and determin-
ing appropriate responses. For example, comparisons of
survival rates among different regions may indicate a
necessity to re-formulate current healthcare plans.
A limitation of this study is that the administrative
data do not include extensive clinical information. For
example, DPC data do not contain information regard-
ing pathological TNM stages and pathological types,
which are provided in current cancer registries’ reports.
Other clinical factors such as comorbidities and co-
treatments may influence patient survival, and their effects
should also be investigated in future analyses. Therefore,
we are unable to make definitive conclusions regarding
the effects of hospital case volumes on survival without
accounting for such factors. However, our results were
compatible with those from previous reports. As our
method provides the ability to rapidly assess overall situa-
tions, DPC data collection criteria can be expanded in the
future to include more clinical information if deemed ne-
cessary for analysis. This would, however, require the need
to weigh the time and effort in implementing additional
data collection against its benefits.
Next, the analyses were limited to tracking data from
one hospital for each patient. The starting date for ana-
lysis of each patient was the initial surgery date for lung
cancer at a DPC hospital. Therefore, there may be time
lapses between the initial diagnosis of cancer and the ini-
tial treatment. We were unable to determine if a patient
had obtained treatment at other hospitals prior to our
analysis, as the data could not be interlinked among the
various institutions. However, the vast majority of treat-
ment for cancer would likely be conducted in specialized
medical institutions, and our method therefore still has
validity in investigating cancer epidemiology in Japan.
Similarly, the data only allow the tracking of patient care
within the same hospital, and patients who subsequently
seek healthcare at other institutions are lost to follow-
up. Thus, the survival rates reported in this study may
be higher than the actual survival rates, as some patients
may have sought healthcare or died in other hospitals or
hospices. We, at this time, assume that most postopera-
tive patients for lung cancer are followed up at the same
hospital where they had undergone surgery, and the ma-
jority of recurrent cases or patients with deteriorating
conditions are likely to be treated at the same hospital.
In addition, some patients may travel a relatively long
distance from their homes to undergo specialized sur-
gery, but receive follow-up care at a closer regional
hospital. As such cases would also be lost to follow-up,
future studies that focus on patients residing in the sameregion as the hospital where they receive care may re-
duce this loss of data.
It should be emphasized that there is a need for data-
bases composed of public data to be systematically de-
signed with the intrinsic capability to integrate with
other databases in order to maximize their contributions
and reduce loss to follow-up. The limitations of the data
source used in this study arose from the lack of integra-
tion across Japanese public databases. The importance of
this study lies in the finding that routinely collected
medical claims data have applications in long-term sur-
vival analyses. While registry databases are undeniably
useful, the integration of other large databases, such as
those comprising claims data, should be considered in
the analysis of any healthcare topic. Although further
studies are needed to improve the follow-up ability of
the data and reduce possible bias due to the aforemen-
tioned limitations, the integration of data sources is an
essential step for improving health services research. In
order to both strengthen the validity of analyses similar
to this study and reinforce registry databases, public data-
base systems should be designed to allow for integration
with other databases. We believe that the further discov-
ery and validation of effective applications of administra-
tive claims databases would support the provision of
up-to-date information to help improve healthcare quality
and outcomes.
Conclusions
We conducted survival analyses of postoperative non-
small cell lung cancer patients using a Japanese adminis-
trative claims database, which covered a wide range of
hospitals that included providers not enrolled in any
cancer registry. Our findings were consistent with previ-
ous reports using analyses of registries, showing that this
methodology may have applications as a useful outcomes
measurement tool for medical staff and policymakers.
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